Custom posters

Qualigen Therapeutics Presents Three QN-302 Posters at American Association of Cancer Research Conference

Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.

Data Highlights In Vivo To research and potential mechanism of action in pancreatic and prostate cancers

CARLSBAD, Calif., April 12, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with designation potential drugs, while commercializing diagnostics, today highlights three posters presented at the American Association of Cancer Research (AACR) held in New Orleans April 8-13, 2022.

Qualigen President and CEO Michael Poirier said, “Our lead QN-302 therapeutic program may have the potential to ultimately treat multiple tumor types characterized by genomic quadruplexes (G4s) that are overrepresented in many related genes. to cancer. The results reported in these posters illustrate live anti-proliferative activity against pancreatic cancer and metastatic prostate cancer. We are encouraged by the results of these studies as we move towards our goal of improving the lives of cancer patients, and we are well on our way to initiating studies enabling IND.

Pancreatic cancer remains a high unmet medical need with limited treatment options. According to the American Cancer Society, approximately 62,210 people will be diagnosed with pancreatic cancer in the United States. in 2022, and more than 49,830 patients will die from the disease – the highest death rate of any major cancer. For advanced disease, chemotherapy (sometimes combined with targeted drug therapy) can prolong survival.1

Poster 2926, “Design based on the structure of fourplex-binding small molecule compounds: The essential role of water molecules » (Dr Stephen Neidle) Crystal structures and computer modeling have been used to characterize the details of the interactions of substituted naphthalene diimides targeted against human DNA quadruplexes, and in particular the role of water molecules in the binding site . It is concluded that information on conserved water molecules is important for drug design and has been used in the design of a current lead compound QN-302.



Session Category: Chemistry
Session title: Structural and chemical biology
Date and time of the session: Tuesday, April 12, 2022, from 9:00 a.m. to 12:30 p.m.
Location: New Orleans Convention Center, DH Exhibit Halls, Poster Section 40

Poster 4068, “The powerful fourplex– binding compound QN-302 shows potent anti-proliferative activity in a panel of prostate cancer cells and anti-tumor activity in a live metastatic prostate cancer model » (Dr. Stephen Neidle) demonstrated bioavailability and tolerance at therapeutic doses in a prostate cancer cell line, PC3, which is derived from castration-resistant prostate cancer and is therefore relevant in the situation where hormonal therapies are no longer effective. the live The study, which included the commonly used drug abiraterone, showed that QN-302 had statistically significant antitumor activity in this model (p=0.0008) compared to controls, and was superior to abiraterone.


Session Category: Experimental and Molecular Therapeutics
Session Title: New Chemotherapy Agents
Date and time of the session: Wednesday, April 13, 2022, from 9:00 a.m. to 12:30 p.m.
Location: New Orleans Convention Center, DH Exhibit Halls, Poster Section 27

Poster 4069, ” The powerfull fourplex– binding compound QN-302 shows anti-tumor activity in patient derivatives in long live models of pancreatic cancer (Dr. Stephen Neidle) described a study in which QN-302 displayed substantial anti-tumor activity in three patient-derived xenograft (PDX) models for pancreatic ductal adenocarcinoma (PDAC). Immunocompromised mice were implanted subcutaneously with PDX tumor fragments. The mice received intravenously either QN-302, a vehicle, or, in some models, gemcitabine. In three of these models, significant changes in tumor growth were observed in those who received QN-302, as well as good tolerance and bioavailability at therapeutic doses.


Session Category: Experimental and Molecular Therapeutics
Session Title: New Chemotherapy Agents
Date and time of the session: Wednesday, April 13, 2022, from 9:00 a.m. to 12:30 p.m.
Location: New Orleans Convention Center, DH Exhibit Halls, Poster Section 27

QN-302 is the Company’s genomic quadruplex (G4) selective transcription inhibitor being developed as a potential treatment for PDAC, in addition to other tumors with high unmet clinical need. Abstracts accepted by the AACR describe potential quadruplex target binding for the compound, as well as significant anti-tumor activity in relevant animal models.

The AACR conference, held in New Orleans April 8-13, 2022, is a focal point for the cancer science community where scientists, clinicians, other healthcare professionals, survivors and patients examine the latest advances in cancer science and medicine.

On Qualigen Therapeutic, Inc.

Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer, as well as maintaining and expanding its FDA-approved FastPack core.® System successfully used in diagnostics for over 20 years. Our investigational compound QN-302 is a small molecule selective transcriptional inhibitor with high binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing G4s against “unwinding”, help inhibit the proliferation of cancer cells. Our investigational compound QN-247 inhibits nucleolin, a key multifunctional regulatory protein that is overexpressed in cancer cells; QN-247 could thus be able to inhibit cell proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (AML). Qualigen’s investigational RAS-F family of small molecule inhibitors of RAS oncogene protein-protein interaction compounds are thought to inhibit or block the binding of proteins from mutated RAS genes to their effector proteins, leaving the mutated RAS proteins incapable of causing further harm. In theory, such a mechanism of action may be effective in treating around a quarter of all cancers, including some forms of pancreatic, colorectal and lung cancers. In addition to its oncology drug pipeline, Qualigen has a well-established diagnostics business that manufactures and distributes proprietary, highly accurate rapid blood test systems to medical practices and small hospitals for the management of prostate cancer and other diseases and health problems.

For more information about Qualigen Therapeutics, Inc., please visit

avant-garde Declarations

This press release contains forward-looking statements by Qualigen that involve risks and uncertainties and reflect the judgment of the Company as of the date of this release. These statements include those relating to the Company’s outlook and strategy for the development of therapeutic drug candidates. Actual events or results may differ from the Company’s expectations. For example, there can be no assurance that the Company will successfully develop any drugs (including QN-302, QN-247 and RAS-F); that the preclinical development of the Company’s drugs (including QN-302, QN-247 and RAS-F, and the deprioritized infectious disease drug candidate QN-165) will be completed on schedule or will be successful; that any clinical trial will be approved to commence or will proceed as anticipated by any anticipated schedule, or at all; that all data from future clinical trials will be favorable or that such trials will confirm any improvement over other products or have no negative impacts; that any drug will receive required regulatory approvals (or Fast Track designation or orphan drug status) or be commercially successful; that patents will issue on patent applications owned and licensed by the Company; that these patents, if any, and the patents currently owned and licensed by the Company would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company’s potential therapeutic products (including QN-302, QN-247 and RAS-F, and QN-165); or that the Company will be able to maintain or expand market demand and/or market share for the Company’s diagnostic products. The Company’s stock price could be adversely affected if any of the events or trends contemplated by the forward-looking statements do not occur or are delayed or if any actual future event otherwise differs from expectations. Additional information regarding these and other risk factors affecting the Company’s business may be found in the Company’s previous filings with the Securities and Exchange Commission, including its most recent Form 10-K, which are all available on

The Company disclaims any intention or obligation to update these forward-looking statements beyond the date of this press release, except as required by law. This warning is made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


Jules Abraham
JQA Partners, Inc.
[email protected]

Source: Qualigen Therapeutics, Inc.